Antiviral Agents

Publisher Website
Google Scholar
Abstract
SINCE the subject of antiviral chemotherapy was last reviewed in the Journal in 1973,1 remarkable progress has been made. Some of the drugs reviewed at that time, e.g., idoxuridine and cytarabine (cytosine arabinoside), as well as the technique of photodynamic inactivation, have been found wanting in well-controlled clinical studies.2 3 4 5 However, agents such as vidarabine (adenine arabinoside) and human leukocyte interferon have undergone extensive clinical testing with encouraging results,6 7 8 9 10 and newer agents with marked selective antiviral activity, such as acyclovir, have been developed.11 , 12 The strides made reflect a greater understanding of the interactions between viruses and cells as well as a . . .